HSS Journal

, Volume 2, Issue 2, pp 130–135 | Cite as

How Much Calcium Is in Your Drinking Water? A Survey of Calcium Concentrations in Bottled and Tap Water and Their Significance for Medical Treatment and Drug Administration

  • Simon Morr
  • Esteban Cuartas
  • Basil Alwattar
  • Joseph M. Lane
Original Article



Different forms of water vary in calcium content. High divalent ion (i.e., Ca2+, Mg2+, etc.) concentration is deleterious to the absorption and efficacy of the bisphosphonate group of drugs in osteoporosis treatment. Water with high calcium concentration may also present an alternate pathway of calcium administration. In either case, knowing the actual concentration is critical.


The current paper is a surveillance study. We hypothesize that there is considerable variation in the calcium concentrations in the various water sources: tap water from US and Canadian cities of different regions and purified, spring, and mineral bottled waters. In addition, we hypothesize that the water filter removes a significant amount of minerals including calcium from the water.


Calcium concentrations in various city tap waters, as well as an assorted number of bottled waters, were determined through the direct inspection of scientific data. The effect of filtering was also determined by mineral analysis of mineral water directly before and after filtration.


The calcium concentration of water varies from 1 to 135 mg/L across the USA and Canada. Most spring waters were found to have a relatively low calcium concentration, with an average of 21.8 mg/L. Purified waters contain a negligible calcium concentration. Mineral waters, on the other hand, were generally found to contain higher calcium concentrations, an average of 208 mg/L of calcium. Filtration was found to remove a considerable amount of calcium from the water, removing 89% on average.


Calcium concentration in water varied substantially from different sources in the USA and Canada. Bottled waters presented with concentrations of calcium covering a very large range. Certain tap and bottled waters present with concentrations of calcium sufficient to exhibit a deleterious effect on bisphosphonate treatment. Alternatively, certain waters may be used as a source of calcium that may provide over 40% of the recommended daily intake for calcium.

Key words

bioavailability bisphosphonate calcium supplements filter water 


  1. 1.
    Reid IR, Ames RW, Evans MC et al (1993) Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J 328:460–464CrossRefGoogle Scholar
  2. 2.
    Shea B, Wells G, Cranney A et al (2002) Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23:552–559CrossRefPubMedGoogle Scholar
  3. 3.
    National Institutes of Health (1994) Optimal calcium intake. NIH Consens Statement 12:1–31Google Scholar
  4. 4.
    Dawson-Hughes B (1998) Vitamin D and calcium: recommended intake for bone health. Osteoporos Int 8:S30–S34PubMedGoogle Scholar
  5. 5.
    Nordin BEC (2000) Calcium requirement is a sliding scale. Am J Clin Nutr 71:1381–1383PubMedGoogle Scholar
  6. 6.
    Dawson-Hughes B, Harris S, Krall S et al (1997) Effect of calcium and vitamin-D supplementation on bone density in men and women 65 years or age or older. N Engl J Med 337:670–676CrossRefPubMedGoogle Scholar
  7. 7.
    Wu DD, Boyd RD, Fix TJ et al (1990) Regional patterns of bone loss and altered bone remodeling in response to calcium deprivation in laboratory rabbits. Calcif Tissue Int 47:18–23PubMedCrossRefGoogle Scholar
  8. 8.
    Espallargues M, Sampietro-Colom L, Estrada MD et al (2001) Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 12:811–822CrossRefPubMedGoogle Scholar
  9. 9.
    National Institutes of Health (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 17:1–45Google Scholar
  10. 10.
    Valtin H (2002) “Drink at least eight glasses of water a day.” Really? Is there scientific evidence for “8 × 8”?. Am J Physiol Regul Integr Comp Physiol 283:R993–R1004PubMedGoogle Scholar
  11. 11.
    Böhmer H, Müller H, Resch KL (2000) Calcium supplementation with calcium-rich mineral waters: a systematic review and meta-analysis of its bioavailability. Osteoporos Int 11:938–943CrossRefPubMedGoogle Scholar
  12. 12.
    Janner M, Muhlbauer RC, Fleisch H (1991) Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int 49:280–283PubMedCrossRefGoogle Scholar
  13. 13.
    Hosking D, Chilvers CED, Christiansen C et al (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 228:485–492CrossRefGoogle Scholar
  14. 14.
    Lieberman UA, Weiss SR, Bröll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443CrossRefPubMedGoogle Scholar
  15. 15.
    Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610CrossRefPubMedGoogle Scholar
  16. 16.
    Saag KG, Emkey R, Schnitzer T et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299CrossRefPubMedGoogle Scholar
  17. 17.
    Devogelaer JP, Broll H, Correa-Potter R et al (1996) Oral alendronate induced progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141–150CrossRefPubMedGoogle Scholar
  18. 18.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  19. 19.
    Lin JH (1996) Bisphosphonates: review of their pharmacokinetic properties. Bone 18:75–85CrossRefPubMedGoogle Scholar
  20. 20.
    Rodan GA, Seedor JG, Balena R (1993) Preclinical pharmacology of alendronate. Osteoporos Int 3:S7–S12CrossRefPubMedGoogle Scholar
  21. 21.
    Dunn CJ, Goa KL (2001) Risedronate, a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61:685–712CrossRefPubMedGoogle Scholar
  22. 22.
    Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315–328CrossRefPubMedGoogle Scholar
  23. 23.
    Laitinen K, Patronen A, Harju P et al (2000) Timing of food intake has a marked effect on the bioavailability of clodronate. Bone 27:293–296CrossRefPubMedGoogle Scholar
  24. 24.
    Merck and Co. Fosamax® Alendronate Sodium (Prescribing Information). Downloaded from Fosamax.com on July 7, 2003Google Scholar
  25. 25.
    P&G Pharmaceuticals. Actonel® Risendronate Sodium (Prescribing Information) Downloaded from Actonel.com on July 7, 2003Google Scholar
  26. 26.
    Brown TL, LeMay HE, Bursten BE et al (2003) Chemistry: The Central Science Ninth edition Upper Saddle River, New Jersey Prentice Hall, p. 684Google Scholar
  27. 27.
    Sheikh MS, Santa Ana CA, Nicar MJ et al (1987) Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 317:532–536PubMedCrossRefGoogle Scholar
  28. 28.
    Heaney RP, Dowell MS, Barger-Lux MJ (1999) Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int 9:19–23CrossRefPubMedGoogle Scholar
  29. 29.
    Rozen GS, Rennert G, Dodiuk-Gad RP et al (2003) Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche. Am J Clin Nutr 78:993–998PubMedGoogle Scholar

Copyright information

© Springer Verlag 2006

Authors and Affiliations

  • Simon Morr
    • 1
  • Esteban Cuartas
    • 2
  • Basil Alwattar
    • 3
  • Joseph M. Lane
    • 1
  1. 1.Hospital for Special SurgeryNew YorkUSA
  2. 2.Jackson Memorial HospitalMiamiUSA
  3. 3.NYU Medical CenterNew YorkUSA
  4. 4.Department of Orthopaedic SurgeryWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations